Our Focus
The Colorado Chapter of the National Bleeding Disorders Foundation (NBDF Colorado) is responsible for addressing the challenges bleeding disorder patients and their families face through education, advocacy, and empowerment.
El Capítulo de Colorado de la Fundación Nacional de Trastornos Hemorrágicos (NBDF Colorado) es responsable de abordar los desafíos que enfrentan los pacientes con trastornos hemorrágicos y sus familias a través de la educación, la defensa y el empoderamiento.
Our Mission ... In Action
-
We connect people in the bleeding disorder community to available, applicable resources and to one another. Through connection we don't have to go through this alone.
-
We fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
-
We are committed to trailblazing the way for those affected by bleeding disorders. We encourage our community members to step out into nature, to forage ahead on their own path of independence.
-
We are committed to educating people inside and outside the bleeding disorder community. Education is empowerment and we strive to encourage independence through learning.
News Articles
The National Bleeding Disorders Foundation (NBDF) has joined with World Federation of Hemophilia (WFH) with issuing a joint statement on a severe adverse event with marstacimab rebalancing agent for hemophilia (Hympavzi®). NBDF believes it is important for the community to be informed as quickly and thoroughly as possible about all adverse events that can impact people’s informed decision-making regarding their treatment. As Pfizer shares more information regarding their ongoing investigation into this event, NBDF will continue to update the community.
The National Bleeding Disorders Foundation (NBDF) is delighted to announce that Luke Luckey of Manchester, Michigan, was selected as the recipient of the 2025 Kevin Child Scholarship (KCS). The Child family selected Luke as this year’s KCS award recipient from among more than 20 applicants.
Hemab Therapeutics recently announced positive results from a Phase 2 clinical study of their investigational subcutaneous therapy sutacimig.
Sutacimig is a laboratory-engineered bispecific antibody being developed as the first-ever prophylactic treatment for individuals with Glanzmann thrombasthenia (GT), one of several diseases the company is looking to ultimately target with this investigational, sub-Q therapy.
